Jefferies puts Amgen on hold

Amgen, Inc. was given a hold rating by Jefferies & Co., Inc. analyst Adam Walsh as IMS numbers indicate Aranesp and Enbrel may post stronger-than-expected second-quarter 2006 sales. The analyst believes that CERA will remain an overhang for Amgen shares in the second half of the 2006. Shares of the Thousand Oaks, Calif.-based biotechnology company were up 38 cents, or 0.59%, at $64.56 on volume of 12,166,608 shares versus the three-month running average of 8,811,910 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.